Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid [0.03%]
Tarlatamab治疗肺类癌患者的临床反应
Jessica S Ross,Jake Lee,Eduardo Ortiz et al.
Jessica S Ross et al.
Background: Pulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine tumor of the lung. In patients with metastatic disease, systemic therapies typically have low response rates, and long-term survival is po...
Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report [0.03%]
肿瘤突变负荷作为预测晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗后发生相关不良事件的标志物：简报报告
Federica Pecci,Xinan Wang,Valentina Santo et al.
Federica Pecci et al.
Background: Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about ...
Preserving Disease Control: The Role of Local Ablative Therapy in EGFR-Mutant NSCLC [0.03%]
EGFR突变型NSCLC的疾病控制：局部消融治疗的作用
Sharareh Gholamin,Matthew Lee,Christine Lovly et al.
Sharareh Gholamin et al.
A Response to the Letter to the Editor: Radiotherapy to the Primary, With or Without Total Metastatic Ablation [0.03%]
编辑来信的答复：原发灶放射治疗，伴或不伴有全身转移灶消融治疗
Shankar Siva,Stephen V Liu,Alexander V Louie
Shankar Siva
Emily Stone,Alex A Adjei
Emily Stone
Clarifying the Evidentiary Boundaries of Primary-Tumor Radiotherapy in Stage IV NSCLC [0.03%]
明确姑息性放疗在四期非小细胞肺癌中的证据边界
Stefania Martini,Elvio Grazioso Russi
Stefania Martini
Jean-Louis Pujol,Upal Basu Roy,Jill Feldman et al.
Jean-Louis Pujol et al.
In the past, people with lung cancer received less public recognition and fewer organized support systems, compared with other cancer communities (such as pediatric or breast cancer). In the 1990s, limited benefit from systemic therapies di...
Exploring the Continuum of HER2 TKD Mutations and HER2 "Sensitizing Mutations" in NSCLC and Retiring the Term "HER2 Exon 20 Insertions" [0.03%]
探索NSCLC中HER2 TKD突变和HER2“敏化突变”连续谱及放弃使用“HER2外显子20插入”这一术语
Xiaosong Li,Kang Qi,Sai-Hong Ignatius Ou et al.
Xiaosong Li et al.
Francesca Bersani,Paolo Bironzo
Francesca Bersani